Boji Medical secures patent for nasal spray formulation

Guangzhou Boji Medical & Biotechnological (SZSE:300404) announced that it has received an invention patent certificate from the State Intellectual Property Office for its nasal spray formulation designed to treat rhinitis. The patented invention, titled "Nasal administration preparation, preparation method and application for treating rhinitis," is numbered ZL2024 1 1731057.9. Filed on November 29, 2024, and authorized on March 7, 2025, the formulation is characterized by low nasal cilia irritation, high water solubility, high bioavailability, and stable formulation. Boji Medical anticipates that this patent will bolster its technological innovation, strengthen its intellectual property protection, and enhance its core competitiveness, though it is not expected to have a significant impact on the company's immediate operating results. The announcement was officially released on March 8, 2025.